Therapeutic approaches involving PGM3 inhibition, and possibly inhibition of protein O-GlcNAcylation, in combination with GEM could be promising to bypass the drug resistance in pancreatic cancer. The gene discussed is PGM3; the disease is pancreatic neoplasm.